CCR2 and B-cell chronic lymphocytic leukemia: To test this hypothesis, we used either clodronate liposomes (CLL) or anti-CCR2 antibodies30 to deplete monocytes/macrophage 24 h after the initial dose of OVT but prior to injection of the second dose.